Labetalol in the control of cardiovascular responses to electroconvulsive therapy in high-risk depressed medical patients.
Labetalol, a drug with alpha- and beta-adrenergic receptor blocking effects, was used to attenuate hypertension and tachycardia associated with electroconvulsive therapy (ECT) in a series of 11 elderly patients with refractory depression and cardiovascular disease in a placebo-controlled, double-blind crossover study design. As compared with placebo, labetalol was found to blunt mean arterial pressure (MAP) increase by up to 8.26% (p less than .001), heart rate increased by up to 26.07% (p less than .001), frequency of atrial arrhythmias by up to 100% (p less than .01), and premature ventricular contractions by 41.97%. No untoward side effects were observed, and no effect on treatment outcome was noted. Labetalol appears to be an effective and safe agent to use in decreasing hypertension, tachycardia, and possibly arrhythmias in high-risk medical patients with cardiovascular disease undergoing ECT.
Stoudemire
A
A
Department of Psychiatry, Emory University School of Medicine, Atlanta, Ga.
Knos
G
G
Gladson
M
M
Markwalter
H
H
Sung
Y F
YF
Morris
R
R
Cooper
R
R
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000150:complications*; D003866:Depressive Disorder / Q000150:complications / Q000628:therapy*; D004311:Double-Blind Method; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000517:prevention & control*; D007741:Labetalol / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013610:Tachycardia / Q000517:prevention & control
D010919:Placebos; D007741:Labetalol